DART Therapeutics is a novel biotechnology firm with a new model for accelerating therapy development and funding for pediatric rare diseases. Founded and funded by Patient Foundations Charley’s Fund and the Nash Avery Foundation, DART is presently focused on Duchenne Muscular Dystrophy (DMD), a fatal disease for which there are no curative therapies.

iStock_000015880197SmallAbout DART Therapeutics »
DART’s mission is to make DMD a chronic, manageable disease.

iStock_000001051305SmallThe DART Model »
Delivering therapies for rare diseases quickly and cost-effectively.

iStock_000004045779SmallDART’s Pipeline »
HT-100 is a small molecule drug candidate being developed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients.